Castle Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 days.
- Its last 6 Sell calls were followed by a 5% average decline over the next quarter.
- Recent price momentum is -4.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 6.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 79.4% | Better than 90% |
| Operating margin | -12.4% | Better than 14% |
| Net margin | -7.0% | Better than 17% |
| Return on equity | -5.2% | Better than 23% |
| Return on invested capital | -6.8% | Better than 20% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -3.9% | Better than 65% |
| 6-month return | 63.1% | Better than 97% |
| 12-month return (ex latest month) | -12.7% | Better than 20% |
| Distance below 52-week high | 25.8% | Better than 49% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.3x | Better than 87% |
| Debt to assets | 6.4% | Better than 76% |
| Interest coverage | -342.2x | Better than 3% |
| Free cash flow / net income | 200.3% | Better than 77% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 47.0% | Better than 64% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 33.41
- Open
- 32.76
- Day range
- 32.54 - 33.38
- Avg price
- 32.85
- Volume
- 309.22K
- Turnover
- 10.16M
- Turnover ratei
- 1.13%
- Volume ratioi
- 0.70
- Amplitudei
- 2.53%
- 52-week rangei
- 17.72 - 44.28
Valuation
- P/Ei
- -39.59
- P/E (TTM)i
- -43.24
- P/Bi
- 2.12
- EPSi
- -0.83
- Book value / shi
- 15.53
- Net profit
- -25.58M
- Net assets
- 478.45M
Share structure
- Market cap
- 1.01B
- Float capi
- 902.87M
- Shares out
- 30.82M
- Float sharesi
- 27.48M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-07-25
25.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.55M net over the window
Short interest
- Shares short
- 2.11M
- % of floati
- 6.90%
- Days to coveri
- 6.06
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Castle Biosciences (CSTL)?
Castle Biosciences last traded at 32.86. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Castle Biosciences's market cap?
About 1.01B.
What is the P/E ratio of Castle Biosciences?
The trailing twelve-month P/E is -43.24. The Valuation tab shows it against the stock's own five-year range.
Does Castle Biosciences pay a dividend?
Castle Biosciences does not currently pay a regular dividend.
Is Castle Biosciences a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 48.29, which implies 47.0% upside from the current price. This is not investment advice.
What is Castle Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Castle Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Castle Biosciences discussion 0 comments